Thermo Fisher buys Belgium's Henogen for nearly $880mn

Medical device maker Thermo Fisher Scientific Inc said on Friday it has completed acquisition of Henogen SA, a Belgium-based viral vector manufacturing business, for about 725 million euros ($879.72 million) in cash.

The acquisition will help expand Thermo Fisher's capabilities for cell and gene vaccines and therapies, the company said.

Thermo Fisher bought Henogen from contract manufacturing services provider Novasep.